Interleukin-5 as a potential target for asthma treatment

Drug News and Perspectives

Volumn 13, Issue 4, 2000, Pages 197-205

  Van Wauwe, J ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 5 AMINO 3 (4 CHLOROPHENYL) 1 [(METHYLAMINO)THIOCARBONYL] 1H 1,2,4 TRIAZOLE; ALPHA INTERFERON; ANTIINFLAMMATORY AGENT; AZAURACIL; CILOMILAST; CYCLOSPORIN A; GAMMA INTERFERON; GLUCOCORTICOID; IMIQUIMOD; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 5; INTERLEUKIN 5 RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; M 50367; MEPOLIZUMAB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONOCLONAL ANTIBODY; MONTELUKAST; PHOSPHODIESTERASE IV INHIBITOR; PNU 142731A; R 146225; RECEPTOR BLOCKING AGENT; RESIQUIMOD; ROLIPRAM; SCH 55700; UNCLASSIFIED DRUG;

ASTHMA; CYTOKINE RELEASE; DRUG TARGETING; EOSINOPHIL; EOSINOPHILIA; GENETIC TRANSCRIPTION; HELPER CELL; PATHOPHYSIOLOGY; PROTEIN STRUCTURE; RECEPTOR BLOCKING; REVIEW; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

EID: 0033851362     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. The cells of the allergic response
2. Updates on cells and cytokines. Human eosinophils
3. Eosinophils in allergy: Role in disease, degranulation, and cytokines
4. Pro-eosinophilic cytokines in asthma
5. Pharmacological implications of interleukin-5 in the control of eosinophilia
6. Simple understanding and optimistic strategy for coping with atopic diseases
7. Biology of interleukin-5 and its relevance to allergic disease
8. Biology of IL-5 in health and disease
9. Role of IL-5 in the development of allergen-induced airway hyperresponsiveness
10. The inhibition of interleukin-5 in allergic diseases
11. Cytokines as targets for the inhibition of eosinophilic inflammation
12. Interleukin-5 and its receptor
13. IL5 and its receptor: Which role do they play in the immune response?
14. A novel dimer configuration revealed by the crystal structure at 2.4Å resolution of human interleukin-5
15. Identification of receptor-binding domains on human interleukin-5 and design of an interleukin-5-derived receptor antagonist
16. An interleukin-5 mutant distinguishes between two functional receptors in human eosinophils
17. A human high affinity interleukin-5 receptor is composed of an IL-5 specific alpha chain and beta chain shared with the receptor for GM-CSF
18. Expression cloning of the human IL-3 receptor cDNA reveals a shared beta-subunit for the human IL-3 and GM-CSF receptors
19. Interleukin-5 and B cell differentiation
20. JAK2 and JAK1 constitutively associate with an IL-5 receptor alpha and beta C subunit, respectively, and are activated upon IL-5 stimulation
21. The activation of the Jak-STAT1 signaling pathway in eosinophils by IL-5
22. Involvement of p59 Lyn T interleukin-5 receptor signaling
23. The signal transduction mechanism of interleukin-5 in eosinophils: The involvement of Lyn tyrosine kinase and the Ras-Raf-1-MEK-microtubule-associated protein kinase pathway
24. Lyn, Jak2 and Raf-1 kinases are critical for the antiapoptotic effect of interleukin-5, whereas only Raf-1 kinase is essential for eosinophil activation and degranulation
25. IL-5 gene transcription in atopic diseases
26. Transcriptional regulation of interleukin-5 gene expression in human T-cells
27. Of the GATA-binding proteins, only GATA-4 selectively regulates the human interleukin-5 gene promoter in interleukin-5 producing cells with express multiple GATA-binding proteins
28. Characterization of the human interleukin-5 gene promoter: Involvement of octamer binding sites in the gene promoter activity
29. Nuclear factor of activated T cells and YY1 combine to repress IL-5 expression in a human T cell line
30. Binding of YY1 and Oct1 to a novel element that downregulates expression of IL-5 in human T cells
31. Role of nuclear factor of activated T cells (NFAT) in the expression of interleukin-5 and other cytokines involved in the regulation of hematopoietic cells
32. Inhibition of pulmonary eosinophilia and hyperreactivity by antibodies to interleukin-5
33. Pharmacokinetics and pharmacodynamics of SB 240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys
34. Conquering airway inflammation in the 21st century
35. SB 240563, a humanized anti-IL-5 monoclonal antibody. Initial single dose safety and activity in patients with asthma
36. Therapeutic strategies for allergic diseases
37. A novel Lyn-binding peptide inhibitor blocks eosinophil differentiation, survival and airway eosinophilic inflammation
38. Inhibitors of p38 MAP kinase: Therapeutic intervention in cytokine-mediated diseases
39. SB203580, an inhibitor of p38 mitogen-activated protein kinase, enhances constitutive apoptosis of cytokine-deprived human eosinophils
40. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase
41. Synthesis and pharmacological activity of triazol derivatives inhibiting eosinophilia
42. Inhibition of pulmonary eosinophilia does not necessarily prevent the airway hyperresponsiveness induced by Sephadex beads
43. Efficacy of inhaled corticosteroids in asthma
44. Glucocorticoids: Mechanism of action and anti-inflammatory potential in asthma
45. Trial of cyclosporin in corticosteroid-dependent chronic severe asthma
46. Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma
47. Cyclosporin A and FK506 reduce interleukin-5 mRNA abundance by inhibiting gene transcription
48. The mechanism of action of cyclosporin A and FK506
49. FK506 and cyclosporin A: Immunosuppressive mechanism of action and beyond
50. Regulation of antigen-induced human T-lytnphocyte responses by calcineurin antagonists
51. Selective suppression of IL-5 synthesis by OM-01 pinpoint treatment of atopic diseases by IL-5 gene transcription inhibition
52. Phosphodiesterase isozymes: Molecular targets for novel anti-asthma agents
53. In vitro down-regulation of antigen-induced IL-5 gene expression and protein production by cAMP-specific phosphodiesterase type 4 inhibitor
54. Differential efficacy of lymphocyte-and monocyte-selective pretreatment with a type 4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene expression
55. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: In vitro anti-inflammatory actions
56. Phosphodiesterase inhibitors reduce bronchial hyperreactivity and airway inflammation in unrestrained guinea pigs
57. Inhibition of allergen-induced lung eosinophilia by type III and combined type III- and type IV-selective phosphodiesterase inhibitors in Brown-Norway rats
58. Anti-inflammatory and bronchodilator properties of RP73401, a novel and selective phosphodiesterase IV inhibitor
59. The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP 840) on allergen-induced responses in asthmatic subjects
60. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B
61. Interleukin-10, a potent immunosuppressant
62. B7/CD28-dependent IL-5 production by human resting T cells is inhibited by IL-10
63. Interleukin-10 inhibits antigen-induced cellular recruitment into the airways of sensitized mice
64. + cells
65. Interferon-alpha for atopic dermatitis
66. Effects of interferon-alpha-2b on the clinical cause, inflammatory infiltration and peripheral blood lymphocytes in patients with severe atopic eczema
67. Interferon-alpha treatment of 6 patients with the idiopathic hypereosinophilic syndrome
68. Cysteinyl leukotrienes in asthma: Old mediators up to new tricks
69. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma
70. Treatment of asthma with drugs modifying the leukotriene pathway
71. Montelukast, a leukotriene receptor antagonist, inhibits the late airway response to antigen, airway eosinophilia, and IL-5 expressing cells in Brown Norway rats
72. + cells
73. IL-12 as a therapeutic target for pharmacological modulation in immune-mediated and inflammatory diseases: Regulation of T helper l/T helper 2 response
74. Interleukin 12 as a target for modulation of the inflammatory responses in asthma
75. Mucosal IFN-gamma gene transfer inhibits pulmonary allergic responses in mice
76. Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation and Th2 cytokine expression in mice
77. Interleukin-12 inhibits antigen-induced airway responsiveness in mice
78. Local treatment with IL-12 is an effective inhibitor of airway responsiveness and lung eosinophilia after airway challenge in sensitized mice
79. Nebulized but not parenteral IFN-gamma decreases IgE production and normalizes airway function in a murine model of allergen sensitization
80. Aerosolized recombinant interferon-gamma prevents antigen-induced eosinophil recruitment in mouse trachea
81. The effects of nebulized recombinant interferon-gamma in asthmatic airways
82. Effect of single-dose interleukin 12 exposure on interleukin 12 associated toxicity and interferon-gamma production
83. Cancer trial of interleukin 12 halted
84. CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12 and interferon-gamma
85. CpG oligodeoxynucleotides act as adjuvant that switch on T helper 1 (Th1) immunity
86. Cutting edge: Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma
87. Immunostimulatory DNA sequence inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice
88. Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides
89. Immune slitnulation - A class effect of phosphorothioate oligonucleotides in rodents
90. Synthetic oligonucleotides: The development of antisense therapeutics
91. Evaluation of the renal effects of an antisense phosphorothioate oligonucleotide in monkeys
92. Effects of the immunomodulatory agent R-837 on acute and latent herpes simplex virus type 2 infections
93. Effects of the immunomodulator (imiquimod, R-837) alone and with acyclovir on genital HSV-2 infection in guinea pigs when begun after lesion development
94. Inhibition of murine tumor growth by an interferon inducing imidazoquinoline
95. Cytokine induction in mice by the immunomodulator imiquimod
96. Cytokine induction by the immunomodulators imiquimod and S-27609
97. Modulation of Th1 and Th2 cytokine production with the immune response modulators, R-848 and imiquimod
98. An effective oral inducer of interferon in humans
99. Oral R-837 induces interferon in healthy volunteers
100. Preclinical evaluation of anti-inflammatory, activities of the novel pyrrolopyrimidine PNU-142731A, a potential treatment for asthma
101. Effect of an orally active Th1/Th2 balance modulator; M50367, on 1gE production, eosinophilia and airway hyperresponsiveness in mice
102. Cytokine production by phytohaematogglutinin-stimulated human blood cells: Effects of corticosteroids, T cell immunosuppressants and phosphodiesterase IV inhibitors
103. Identification of R146225 as a novel orally active inhibitor of interleukin 5 protein and mRNA production